Piper Sandler Sticks to Its Buy Rating for Insulet (PODD)
Piper Sandler analyst Matthew O’Brien maintained a Buy rating on Insulet (PODD – Research Report) today and set a price target of ...
Insulet’s Growth Trajectory Strengthened by Omnipod 5’s Expansion into Type 2 Diabetes Market
Insulet (PODD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Patrick Wood ...
Medtronic: An Undervalued Stock With Durable Competitive Advantages
Medtronic, a global developer and manufacturer of medical devices for chronic diseases, is now a $111 billion (by market cap) ...
2 Unstoppable Dividend Stocks to Buy Right Now for Less Than $200
Dividend stocks can be a great way to boost your portfolio's returns by generating extra income apart from just stock price appreciation. However, the beauty with dividends lies in their flexibility: ...
The Washington Post26d
Diabetes took over her life, until a stem cell therapy freed her
She would reach for juice boxes stored in her nightstand or fiddle with her pump to release a bolus of insulin ... cancer or other side effects. And the supply of islets was extremely limited.
KHOU 1126d
VERIFYING the difference between $35 insulin caps under Biden and Trump
That’s why the federal government and several drug companies have been working ... durable medical equipment, such as insulin pumps, and many preventive services, like screenings, shots or ...
Stocks to Watch: Topgolf Callaway Brands, Modular Medical, V2X
Topgolf Callaway Brands is splitting the company into two businesses. The Carlsbad, Calif., company said Wednesday that its Callaway golf equipment and fitness apparel business, with about $2.5 ...